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Edited by Horst FeldmannAbstract Cruentaren A, a new antifungal benzolactone pro-
duced by the myxobacterium Byssovorax cruenta, proved to be
highly cytotoxic against various human cell lines. It inhibited
the proliferation of diﬀerent cancer cell lines including a multi-
drug-resistant KB line at low nanomolar levels. It arrested hu-
man histocytic lymphoma cells (U-937) in G0/1 phase, but did
not trigger an apoptotic process. Studies to uncover the molecu-
lar target of cruentaren A showed that the novel compound, de-
spite its structural similarity to the benzolactone enamides
apicularen and salicylihalamide, was no V-ATPase inhibitor.
In contrast, cruentaren speciﬁcally inhibited mitochondrial
FOF1-ATPases with IC50 values of 15–30 nM. Although the ex-
act binding site of cruentaren remains undeﬁned, inhibition was
shown to occur by interaction with the catalytic F1 domain. Since
mitochondrial ATPases play a crucial role in the pathophysiol-
ogy of several human disorders including cancer, cruentaren or
synthetic derivatives thereof could form the basis of future ther-
apeutic strategies.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Cruentaren; Myxobacteria; Benzolactone class;
Cytotoxic activity; Mitochondrial F1-ATPase inhibitor1. Introduction
The Gram-negative, fruiting body forming myxobacteria
have emerged as a particularly rich source of secondary metab-
olites, which are characterised by a multitude of unrelated
structures as well as by diﬀerent biological activities with inter-
esting mechanisms of action [1,2]. The recently described
cruentarens were discovered in extracts of the new myxobacte-
rium Byssovorax cruenta strain By c1 because of the high anti-
fungal activity of cruentaren A, and later on cytotoxicity
against L929 mouse cells was also observed [3]. Structurally
they are characterized by a 12-membered lactone with an allyl-
amine side chain acylated by a 2-hydroxy-4-methoxy benzoic
acid in cruentaren A (Fig. 1) and a corresponding 6-membered
lactone in cruentaren B [4]. Thus, cruentarens are closely re-
lated to the class of benzolactone enamides, including the sal-
icylihalamides and the lobatamides [5,6]. Close structural
similarity also exists to apicularen A, produced by several*Corresponding author. Fax: +49 531 6181 3096.
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doi:10.1016/j.febslet.2007.06.069species of the myxobacterial genus Chondromyces [7–9]. So
far, all members of the benzolactone enamide class have been
described as highly cytotoxic compounds, which speciﬁcally in-
hibit V-ATPases [9–11]. Therefore, we speculated that cruenta-
rens might have the same properties. Hitherto, preliminary
studies [3] had indicated that cruentaren A interferes with
mitochondrial ATPases, complex ubiquitous proteins which
are evolutionarily related to V-ATPases, reﬂected by their sim-
ilar overall structure consisting of a catalytic F1 (V1) domain
and a proton translocating, membrane bound FO (VO) domain
[12–14]. In this article, we report on the growth inhibitory ef-
fect of cruentaren A on various human cell lines and deal with
its inhibitory capacity on ion transporting ATPases. We show
that cruentaren A speciﬁcally inhibits mitochondrial FOF1-
ATPases by interaction with the F1 part, while other ion trans-
porting ATPases such as V-ATPase or Na+/K+-ATPase re-
main unaﬀected.2. Materials and methods
2.1. Natural compounds
Cruentaren A and apicularen A were kindly supplied by members of
the former Division of Natural Product Research at the Helmholtz
Centre for Infection Research. Oligomycin was purchased from Sigma.
Concanamycin A was kindly provided by the Institute of Organic and
Biomolecular Chemistry, University of Go¨ttingen.
2.2. Cell culture assays
Cell lines were obtained from the American Type Culture Collection
(ATCC) and the German Collection of Microorganisms and Cell Cul-
tures (DSMZ). All cell lines were cultured under conditions recom-
mended by their respective depositors. Growth inhibition was
measured in microtiterplates by using the MTT assay as reported pre-
viously [15]. In growth kinetic studies with KB-3-1 (DSMZ ACC158)
the inoculum was 50000 cells/ml and as parameter of growth, the pro-
tein concentration of harvested and washed cells was determined at dif-
ferent times using Bradford reagent (Bio-Rad). Cell culture reagents
were purchased from Life Technologies Inc. (Gibco BRL) and plastic
ware was obtained from Nunc.
In order to estimate the amount of inhibitor that is bound to cells,
KB-3-1 cells (500000 in 10 ml) were incubated overnight with
20 ng/ml of cruentaren A and apicularen A, respectively. The cells were
then harvested by scrapping, centrifuged, washed with 10 ml PBS, and
extracted with 0.5 ml methanol. The methanolic extract was evapo-
rated to dryness, suspended in 200 ll of culture medium, and used
for a growth inhibition assay with KB-3-1 cells as mentioned above.
2.3. Caspase measurement
U-937 cells (DSMZ ACC5) were seeded in wells of a 384-well plate
(2500 cells/well) and incubated with cruentaren A (20 ng/ml) for diﬀer-
ent periods of time. Activity of caspase 3 and caspase 7 was measuredblished by Elsevier B.V. All rights reserved.
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Fig. 1. Structure of the cruentaren A.
Table 1
Growth inhibition of diﬀerent human cancer cell lines by cruentaren A
and apicularen A
Cell line Origin IC50 (ng/ml)
Cruentaren A Apicularen A
KB-3-1 Cervix carcinoma 0.3 1.0
KB-V1 Multi-drug resistant
KB line
0.6 10
K-562 Chronic myelogenous
leukemia
0.6 2.0
U-937 Histiocytic carcinoma 0.1 1.5
A-549 Lung carcinoma 0.4 0.1
SK-V-3 Ovarian carcinoma 1.0 1.5
A-498 Kidney carcinoma 0.4 0.3
3524 B. Kunze et al. / FEBS Letters 581 (2007) 3523–3527by using the Apo-One Homogeneous Caspase-3/7 Assay Kit from Pro-
mega.
2.4. Nucleosome quantiﬁcation
The occurrence of mono- and oligonucleosomes due to apoptotic
process was determined in U-937 cells using the Cell Death Detection
ELISA kit from Roche Diagnostic.
2.5. Cell cycle analysis
After the appropriate treatment, 106 U-937 cells were harvested by
centrifugation and then ﬁxed with cold (20 C) 80% methanol. After
30 min of incubation on ice, the cells were washed with phosphate buf-
fered saline (PBS) and then treated with 0.1% saponin in PBS (w/v).
Finally 500 ll propidium iodide (20 lg/ml) and RNAse (1 mg/ml) were
added, and the cells were incubated at 37 C for 30 min. Samples were
analyzed by a FACScan (Becton Dickinson). Results are presented as
the number of cells versus the amount of DNA as indicated by ﬂuores-
cence intensity.
2.6. Enzyme preparations
Yeast mitochondria were obtained as described previously [16]. In
some cases the yeast cells mixed with glass beads were only homoge-
nized in a mini-shaker (Ika). Beef heart mitochondria were isolated
by diﬀerential centrifugation, following the protocol of Smith by using
a blender to homogenize the heart mince [17]. The initial homogenisa-
tion buﬀer consisted of 250 mM sucrose, 10 mM KH2PO4, 10 mM
Tris, 2 mM EGTA, 2 mM MgCl2, pH 7.4, and further isolation proce-
dures were carried out in the same medium without EGTA [18]. Sub-
mitochondrial particles (SMP) were obtained by ultrasonic treatment
of the mitochondria.
To obtain F1-ATPase enriched fractions, submitochondrial particles
were mixed with half of the volume of chloroform for 15 s at room
temperature and immediately centrifuged for 10 min at 6000 rpm to
separate the aqueous and organic phases. The upper aqueous phase
containing the soluble F1 part was carefully removed and assayed
for ATPase activity as described below. F1-ATPase in this fraction is
relatively unstable and sensitive to low temperatures.
The V-ATPase holoenzyme was puriﬁed as published elsewhere [19].
Preparation of highly puriﬁed membranes containing Na+/K+-ATPase
from pig kidney followed the protocol of Jørgensen [20] with three
main steps of diﬀerential centrifugation, incubation with SDS in the
presence of ATP and sucrose density gradient centrifugation in a ﬁxed
angle rotor.
2.7. ATPase assays
Unless otherwise noted, ATPase assays were performed in a total
volume of 160 ll. The preincubation time with or without additional
inhibitor was 5 min and the reactions were stopped at a given time
by placing the tubes into liquid nitrogen.
Assays with submitochondrial particles from beef heart and the
yeast Saccharomyces cerevisiae were carried out at 30 C and consisted
of 4 lg of bovine and 2 lg of yeast protein, respectively, 50 mM Tris–
MOPS, pH 8.1, 1 mM MgCl2, 20 mM KCl, and 12.5 mM NaCl. The
reaction was started with 1 mM ATP and stopped after 2 min of incu-
bation.
ATPase assays with enriched F1-ATPase preparations of both beef
heart and the yeast S. cerevisiae were performed in a ﬁnal volume of
1 ml and a pH of 8.0 at room temperature The samples contained 6–
10 lg of bovine and 14 lg of yeast protein, respectively, 50 mM Tris,50 mM KCl and 2.5 mM MgCl2. After 5 min of preincubation with
or without inhibitors, 5 mM ATP was added, and after an additional
incubation time of 15 min the reaction was stopped by the addition
of 0.4 ml of 20% TCA.
V-ATPase assays were carried out at a pH of 8.1 and consisted of
3 lg of protein, 50 mM Tris–MOPS, 3 mM 2-mercaptoethanol,
1 mM MgCl2, 20 mM KCl, 0.003% C12E10, 20 mM NaCl, and 3 mM
Tris–HCl. After preincubation at 30 C with or without additional
inhibitors, 1 mM Tris–ATP was added and after an incubation time
of 2 min the reactions were stopped by placing the tubes into liquid
nitrogen. Assays using Na+/K+-ATPase were performed at pH 7.5
and contained 0.5 lg of protein, 50 mM Tris–MOPS, 5 mM imidazole,
0.2 mM EDTA, 4 mMMgCl2, 20 mM KCl, 3.1% DMSO and 100 mM
NaCl. After 5 min of preincubation at 37 C the reaction was started
with 3 mM Tris–ATP and stopped after 2 min of incubation by placing
the tubes into liquid nitrogen.
Determination of the inorganic phosphate produced in the assays
with enriched F1 part followed the method of Fiske and Subarrow
[21] using ascorbic acid as reducing agent, while the inorganic phos-
phate produced in the assays of F-ATPase, V-ATPase, and Na+/K+-
ATPase was measured according the protocol of Wieczorek et al. [22].
2.8. Other procedures
Fifth instar larvae of Manduca sexta (Lepidoptera, Sphingidae),
weighing 6–8 g, were reared under long day conditions (16 h of light)
at 27 C using a synthetic diet modiﬁed according to Bell et al. [23].3. Results and discussion
3.1. Growth inhibitory eﬀects of cruentaren A on human cancer
cell lines
The novel antifungal cruentaren A, showing also cytotoxic-
ity against our standard mouse ﬁbroblast cell L929 [3], was
checked for its impact on the growth of a variety of human
cancer cell lines from diﬀerent tissues (Table 1). The IC50 val-
ues were, comparable with those described for other benzolac-
tones such as apicularen A [7,9], in the nanomolar range, even
for the multi-drug-resistant cell line KB-V1.
Fig. 2 shows growth kinetics of KB-3-1 cells in the presence
and the absence of cruentaren A. At a concentration of 20 ng/
ml cruentaren A, the KB-3-1 cells slowly ceased growing. The
protein amount was slightly increasing for about three days.
When the culture medium was replaced by fresh medium with-
out cruentaren A after one, two or ﬁve days, the cells re-started
to propagate transiently, probably due to cellular ATP pro-
duction via glycolysis, but ﬁnally stagnated again after about
2–3 days. This eﬀect of cruentaren A diﬀers from that of the
structurally related V-ATPase inhibitor apicularen A, for
which in comparable assays full reversibility after inhibitor
wash-out had been demonstrated [7].
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Fig. 2. Kinetics of growth inhibition by cruentaren A in KB-3-1 cells.
Control without inhibitor (open circles), with 20 ng/ml of cruentaren A
(solid circles), culture medium replaced by fresh medium without
inhibitor after 1 day (solid triangles), after 2 days (solid squares) and 5
days (solid diamonds). Growth was determined as protein increase.
0 200 400 600 800 1000
0
50
100
150
200
0 200 400 600 800 1000
0
50
100
150
200
0 200 400 600 800 1000
0
50
100
150
200
G2/M
G0/1
A
Co
un
ts
B
Co
un
ts
C
 
Co
un
ts
 Fluorescence
Fig. 3. Histograms of ﬂow cytometry analysis of U-937 cells. In the
presence of cruentaren A (20 ng/ml) the number of cells in G0/1 phase
increased with time. The percentage rose from 31% (A) to 49% after
1 day (B) and 56% after 2 days (C) of incubation.
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be its inﬂuence on the cell cycle. Cell cycle analysis by ﬂow
cytometry of U-937 cells showed that the cells treated with cru-
entaren A arrested in the G0/1 phase (Fig. 3). After one day, the
percentage of cells in G0/1 increased from 31% to 49%, and
to 56% after two days of incubation. Since, we did not observe
an increased sub-G0/1 population, apoptosis induced by cruen-
taren treatment appears improbable. We also measured cas-
pase activity in U-937 cells that had been incubated with
cruentaren A for 1–16 h, but found no increase in activity.
Using an ELISA for mono- and oligo-nucleosomes we also
found no hints for an apoptosis going on after three days of
incubation with cruentaren A, neither with 20 ng/ml nor with
an enhanced concentration of 200 ng/ml. From these results
we assume that the irreversible eﬀect of cruentaren A is not
due to an irreversible induction of apoptosis.
Another reason for the irreversible eﬀect of cruentaren A
may be that it just could not be washed out because of its
strong binding to the cells. Therefore, we tested methanolic ex-
tracts of washed KB-3-1 cells that had been incubated with
cruentaren (20 ng/ml) overnight. In a serial dilution assay,
we still observed a considerable amount of growth inhibition.
The same experiment with apicularen revealed, as expected, no
inhibitory activities of the respective extracts. Thus it appears
that the eﬀect of cruentaren A is predominantly irreversible be-
cause it strongly binds to the target cells.
3.2. Eﬀects of cruentaren A on V- and P-ATPases
Initially, we tested the inhibitory eﬃcacy of cruentaren A on
the V-ATPase since we assumed that it would have the compa-
rable inhibitor characteristics as the closely related published
benzolactone enamides such as apicularen and salicylihalamidewhich exhibit IC50 values in the nanomloar range [9–11].
Therefore, we prepared pure V-ATPase holoenzyme from the
midgut of the tobacco hornworm and tested if cruentaren A
would also block V-ATPase activity. However, even at a con-
centration of 1 lM which is suﬃcient for established speciﬁc
V-ATPase inhibitors such as the plecomacrolides concanamy-
cin and baﬁlomycin or the above mentioned benzolactone ena-
mides to completely inhibit the V-ATPase, cruentaren A
unexpectedly had no eﬀect (Table 2).
To further elucidate the molecular target of the highly cyto-
toxic cruentaren, we tested its eﬀect on the Na+/K+ATPase.
This ion transporting enzyme belongs to the family of P-ATP-
ases and occurs in virtually every animal cell where its main
function is the preservation of sodium gradients across the
plasma membrane [24]. For our experiments we used puriﬁed
Na+/K+-ATPase containing plasma membranes from pig kid-
ney. As shown in Table 2, cruentaren A had no eﬀect on the
activity of the Na+/K+-ATPase even at a concentration of
1 lM, which is much higher than the IC50 values determined
Table 2
Inhibition of the Na+/K+-ATPase and of the V-ATPase by cruen-
taren A
Compound Relative activity (%)
Na+/K+-ATPase V-ATPase
Control without inhibitors 100a 100a
Vanadate 1 mM 4 ± 2.6 n.d.
Concanamycin A1 1 lM n.d. 3.2 ± 1.3
Cruentaren 1 lM 108 ± 9.8 103 ± 24.7
aValues represent the means ± S.E.M. of three independent experi-
ments (n.d. = not determined). The speciﬁc ATPase activity without
inhibitor was 6.1 ± 0.2 lmol mg1 min1 in Na+/K+-ATPase prepa-
rations and 3.2 ± 0.7 in V-ATPase preparations.
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pletely inhibited by the addition of the speciﬁc inhibitor vana-
date (Table 2).
Taken together the results with V- and P-ATPases strongly
indicate that cruentaren A is neither a V-ATPase nor a P-ATP-
ase inhibitor.
3.3. Eﬀects of cruentaren A on F-ATPases
Because cruentaren A did not inhibit V- nor P-ATPases, we
consequently investigated as next step the inhibitory eﬃcacy of
cruentaren A on F-ATPases which intrinsically could have
been suspected from our initial studies with mitochondria [3].
To examine the potency of this eﬀect, we analyzed the dose
dependent inhibition of FOF1-ATPase activity by cruentaren
A in mitochondrial preparations of both beef heart and the
yeast Sacharomyces cerevisiae. Preliminary studies had shown
that about 80% of total ATPase activity in these preparations
were sensitive to the speciﬁc FOF1-ATPase oligomycin [3]. As
Fig. 4 reveals, cruentaren A inhibited the FOF1-ATPase activ-
ity in submitochondrial particles from beef heart and yeast
half-maximally at concentrations between 15 and 30 nM.
The inhibition curve was rather steep with a Hill coeﬃcient
of clearly more than 1, indicating some positive cooperativity
in the inhibition process.0
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Fig. 4. Dose dependent inhibition of F-ATPase activity in submito-
chondrial particles of beef heart and Saccharomyces cerevisiae. In each
case two independent experiments are shown. The speciﬁc ATPase
activity without inhibitor was 1.5 lmol mg1 min1 in beef heart
preparations (solid and open diamonds) and 1.3, respectively
3.9 lmol mg1 min1 in yeast mitochondria (solid and open triangles).The classiﬁcation of cruentarens as members of the salicyli-
halamide/apicularen family on the one hand and the evolution-
ary relationship of V- and F-ATPases [12] on the other hand
imply a possible conserved primary inhibition mechanism or
binding site for this group of antibiotics. A comparable com-
mon mechanism had already been suggested for the V-ATPase
inhibitor baﬁlomycin and the F-ATPase inhibitor oligomycin
[25]. For the benzolactone enamides salicylihalamide and api-
cularen it has been shown recently that inhibition of the V-
ATPase activity is mediated via interaction with the VO-com-
plex as the ATP hydrolysis catalyzed by the isolated V1 com-
plex was not eﬀected (salicylihalamide: [26]; apicularen: Huss
and Wieczorek, unpublished). Although the nature of this
interaction is still unknown, experiments using a radioactively
labelled semisynthetic derivative of concanamycin had shown
that the binding site for apicularen (and thus evidently also
for salicylihalamide) is diﬀerent from that for the plecomacro-
lides [9,19].
3.4. Inhibition of the catalytic F1 domain by cruentaren A
To investigate whether cruentaren A inhibited the F-ATPase
activity in a similar way by targeting the FO-part, we per-
formed assays using samples enriched in F1-ATPase. Contrary
to our expectations, cruentaren A inhibited the activity of F1-
ATPase solubilized from both yeast and beef heart submito-
chondrial particles (Table 3). The inhibitory eﬀect at the con-
centrations of 0.1 and 1 lM was nearly identical to that
obtained with the FOF1-holoenzyme (compare Fig. 4). As ex-
pected, the FO-targeting inhibitor oligomycin did not aﬀect
the F1-ATPase activity. The inhibitory capacity of cruentaren
A appears to be limited to eukaryotic F-ATPases, since it has
been shown to be completely inactive against a series of Gram-
negative bacteria [3], and since it did not inhibit the puriﬁed
F1-ATPase from Escherichia coli (data not shown).
Based on our results, we conclude that cruentaren A inhibits
mitochondrial F-ATPases by targeting the catalytic F1-domain
and not via interaction with the membrane bound FO-domain.
This outcome seems surprising in view of the eﬀect of the re-
lated benzolactone enamides which operate on V-ATPases
via the VO-complex. However, in spite of their planar structural
similarity, conformation and spatial arrangement of functional
groups are quite diﬀerent, as has been shown by X-ray crystal
structure analyses of apicularen A and cruentaren A [4]. From
this point of view it is conceivable that these compounds inter-
act with diﬀerent binding sites in related proteins.
Several natural compounds such as aurovertins or the poly-
phenolic phyto-chemicals resveratrol and piceatannol are well
known inhibitors of mitochondrial F1-ATPases, for whichTable 3
Inhibition of F1 ATPase solubilized from submitochondrial particles
Compound Relative activity (%)
Beef heart S. cerevisiae
Control without inhibitors 100a 100a
Oligomycin 1 lM 99.1 ± 0.1 94.0 ± .2.0
Cruentaren 1 lM 3.3 ± 0.8 3.0 ± 0.7
Cruentaren 0.1 lM 10.0 ± 0.5 10.3 ± 0.7
aValues represent the means ± S.E.M. of three independent experi-
ments. The speciﬁc ATPase activity without inhibitor was
3.9 ± 0.3 lmol mg1 min1 in F1 beef heart preparations and 7.5 ±
0.5 in F1 yeast preparations.
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have no evidence for a cruentaren binding site in the F1-ATP-
ase, further work is urgently required. However, in the light of
our ﬁnding that cruentaren inhibits the mitochondrial F1-
ATPase from two evolutionarily rather distant eukaryotic
organisms such as yeast and mammal but does not inhibit
the F1-ATPase from Escherichia coli, it appears tempting to
speculate that it binds to the F1 subunit e which has no bacte-
rial counterpart [28,29].
Apart from the fact that the inhibitory site needs to be iden-
tiﬁed, our results substantiate that cruentaren A is, to our
knowledge, the most potent inhibitor of mitochondrial F1-
ATPases. A future understanding of the interaction of cruen-
taren with its binding site may enable the rational development
of therapeutic agents for cancer treatment. Although the ther-
apeutic eﬃcacy of cruentaren as anticancer drug has still to be
evaluated, its strong binding to cells might be advantageous,
provided that it is eﬃciently delivered to tumor cells. This
could possibly be done by tumor targeting via antibody or li-
gand conjugation [30,31].
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